MicroRNAs (miRNAs) are non-coding RNA that play pivotal role in modulating expression of multiple target genes at post-transcriptional level and have potential to modulate physiological & pathological processes thus can be used as potential therapeutic targets. In kidney, role of miR have been involved in renal fibrosis, organogenesis and in pathogenesis of many diseases including diabetic, IgA nephropathies, glomerulopathies etc thus opening the possibility of their use as biomarkers in CABMR. The impact of miRNA regulation involved in allograft function and immunity has not been investigated thoroughly thus we studied the miRNAs expression involved in CABMR. Patients with CABMR (Banff’s classification- 2017) were included. 11 blood donors (M=10) with a mean age of 48.7Y were served as controls. Samples were processed for RNA isolation. RNA integrity was checked by running over 1% agarose gel and quantity and qualities were checked using nanodrop with 260/230 and 260/280 ≥ 1.8. The miRNAs expressions, miR-21, miR-155, miR-210, miR-146a, miR-126, miR-34a, miR-150 and RNU6B (control) were detected by quantitative miRNA stem loop RT-PCR technology (TaqMan MicroRNA Assays, Applied Biosystems, CA) as per manufactures protocol. Briefly, we used highly target-specific stem loop structure and reverse transcription primer, and after reverse transcription, used specific TaqMan hybridization probes for miRNA amplification. This allowed for a high specificity only for the mature miRNA, and formation of a reverse transcription primer/mature miRNA chimera extending to the 5’ end of the miRNA. Expression was measured by calculating fold change. Total 24 patients (Male=22 with mean age of 42.63 Y) were enrolled for the study with post transplant duration of 32.25 months. The demographic details with mean values were: S Creatinine = 1.75 mg/dl, BUN = 27.97 mg/dl, Tac level = 6.56 ng/ml, S Uric Acid = 6.778 mg/dl, S Albumin = 3.68 g/dl, Na+/K+ = 135.9/4.21 mmol/L, S Phosphorus = 3.250 mg/dl, S Alkaline phosphate = 81.65 u/L. Induction regimen (Basiliximab=20, ATG= 4) Baseline Immunosuppression MMF+Pred (Tacrolimus/Cyclosporin) = 22/2. C4d were positive in 22 and DSA+ in 2 patients. The expression of different microRNAs, miR-21 (p≤0.0001), miR-155 (p=0.0212), miR-210 (p=0.0001), miR-146a (p=0.0055), miR-126 (p=0.0001) were increased in CABMR patients compared to healthy controls whereas expression of miR-150 (p=0.0006) was shown to be reduced. Expression of miR-34a did not show any significant change. Altered miRNA expression profiling was found in CABMR compared to healthy controls. MicroRNAs are crucial regulators of cell function. They are easy to detect and represent potentially good targets for novel therapies.
Read full abstract